{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:05:21Z","timestamp":1781247921175,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.urolonc.2022.05.016","type":"journal-article","created":{"date-parts":[[2022,6,5]],"date-time":"2022-06-05T07:28:46Z","timestamp":1654414126000},"page":"490.e13-490.e20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer"],"prefix":"10.1016","volume":"40","author":[{"given":"Matteo","family":"Ferro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lucarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Maria","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Crocerossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cantiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Borghesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Papalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Luzzago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Marchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelina","family":"La Civita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Alessandro","family":"Mistretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Piccinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marmiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Ivan","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Schips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Hurle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisto","family":"Perdon\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Del Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavian Sabin","family":"Tataru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Musi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Montanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ottavio","family":"de Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai Dorin","family":"Vartolomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2022.05.016_bib0001","first-page":"E15","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"8","key":"10.1016\/j.urolonc.2022.05.016_bib0002","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2022.05.016_bib0003","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ijc.29670","article-title":"Cancer incidence in five continents: inclusion criteria, highlights from Volume X and the global status of cancer registration: cancer Incidence in five continents volume X","volume":"137","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2022.05.016_bib0004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.05.016_bib0005","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fonc.2020.00102","article-title":"Traditional classification and novel subtyping systems for bladder cancer","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.05.016_bib0006","first-page":"51","article-title":"Adenocarcinoma of the urinary bladder","volume":"3","author":"Dadhania","year":"2015","journal-title":"Am J Clin Exp Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2022.05.016_bib0007","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.aju.2016.07.001","article-title":"Squamous cell carcinoma of the urinary bladder: systematic review of clinical characteristics and therapeutic approaches","volume":"14","author":"Martin","year":"2016","journal-title":"Arab J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.05.016_bib0008","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) Prognostic Factor Risk Groups for Non\u2013muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.05.016_bib0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.05.016_bib0010","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.05.016_bib0011","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijsu.2018.02.045","article-title":"Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized clinical trials","volume":"52","author":"Chen","year":"2018","journal-title":"Int J Surg"},{"issue":"2","key":"10.1016\/j.urolonc.2022.05.016_bib0012","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3233\/BLC-150039","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease","volume":"2","author":"Steinberg","year":"2016","journal-title":"BLC"},{"issue":"16","key":"10.1016\/j.urolonc.2022.05.016_bib0013","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"JCO"},{"issue":"6b","key":"10.1016\/j.urolonc.2022.05.016_bib0014","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1111\/j.1464-410X.2011.10894.x","article-title":"Prognostic significance of Bacillus Calmette-Gu\u00e9rin failure classification in non-muscle-invasive bladder cancer: classification Of BCG failure in NMIBC","volume":"110","author":"Shirakawa","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2022.05.016_bib0015","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.clgc.2021.12.005","article-title":"Impact of age on outcomes of patients with pure carcinoma In Situ of the bladder: multi-institutional cohort analysis","volume":"20","author":"Ferro","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2022.05.016_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.615091","article-title":"Immunological Hallmarks for clinical response to BCG in bladder cancer","volume":"11","author":"Lim","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.05.016_bib0017","first-page":"1737","article-title":"Predictive value of NRAMP1 and HGPX1 gene polymorphism for maintenance BCG response in non-muscle-invasive bladder cancer","volume":"36","author":"Lenormand","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2022.05.016_bib0018","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.redox.2015.08.008","article-title":"Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes","volume":"6","author":"Ryk","year":"2015","journal-title":"Redox Biol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.05.016_bib0019","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bju.12245","article-title":"Incidence and predictors of understaging in patients withclinical T1 urothelial carcinoma undergoing radical cystectomy: predictors of bladder cancer understaging","volume":"113","author":"Ark","year":"2014","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.urolonc.2022.05.016_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non\u2013muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2022.05.016_bib0021","first-page":"284","article-title":"Does restaging transurethral resection of bladder tumour influence outcomes in patients treated with BCG immunotherapy? 491 cases in 20 years\u2019 experience","volume":"14","author":"Krajewski","year":"2019","journal-title":"Wideochir Inne Tech Maloinwazyjne"},{"issue":"1","key":"10.1016\/j.urolonc.2022.05.016_bib0022","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21037\/tau.2018.10.19","article-title":"The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer","volume":"8","author":"Soria","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2022.05.016_bib0023","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fonc.2019.00465","article-title":"Is repeat transurethral resection always needed in high-grade T1 bladder cancer?","volume":"9","author":"Cal\u00f2","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.05.016_bib0024","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1097\/01.ju.0000181799.81119.fc","article-title":"Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy","volume":"174","author":"Herr","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.05.016_bib0025","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.eururo.2017.10.003","article-title":"Predicting response to intravesical bacillus calmette-gu\u00e9rin immunotherapy: Are we there yet? A systematic review","volume":"73","author":"Kamat","year":"2018","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.05.016_bib0026","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC Nomograms and Risk Groups for predicting recurrence, progression, and disease-specific and overall survival in non\u2013muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.05.016_bib0027","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","article-title":"Prognostic factors in patients with non\u2013muscle-invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin: multivariate analysis of data from four randomized CUETO Trials","volume":"53","author":"Fernandez-Gomez","year":"2008","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2022.05.016_bib0028","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrurol.2016.126","article-title":"The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder","volume":"13","author":"Mathieu","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2022.05.016_bib0029","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/cancers13061325","article-title":"The potential of artificial intelligence to detect lymphovascular invasion in testicular cancer","volume":"13","author":"Ghosh","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.urolonc.2022.05.016_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12894-016-0122-1","article-title":"Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Gu\u00e9rin","volume":"16","author":"Fukumoto","year":"2016","journal-title":"BMC Urol"},{"issue":"7","key":"10.1016\/j.urolonc.2022.05.016_bib0031","doi-asserted-by":"crossref","first-page":"FSO709","DOI":"10.2144\/fsoa-2021-0008","article-title":"Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy","volume":"7","author":"Ferro","year":"2021","journal-title":"Future Sci OA"},{"issue":"2","key":"10.1016\/j.urolonc.2022.05.016_bib0032","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1590\/s1677-5538.ibju.2018.0249","article-title":"Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?","volume":"45","author":"Racioppi","year":"2019","journal-title":"Int Braz J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2022.05.016_bib0033","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2022.05.016_bib0034","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with Bacille Calmette-Gu\u00e9rin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"issue":"31","key":"10.1016\/j.urolonc.2022.05.016_bib0035","doi-asserted-by":"crossref","first-page":"e16223","DOI":"10.1097\/MD.0000000000016223","article-title":"The impact of age on intravesical instillation of Bacille Calmette\u2013Guerin treatment in patients with high-grade T1 bladder cancer","volume":"98","author":"Cal\u00f2","year":"2019","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.urolonc.2022.05.016_bib0036","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jjco\/hyq241","article-title":"Could patient age influence tumor recurrence rate in non-muscle-invasive bladder cancer patients treated with BCG immunotherapy?","volume":"41","author":"Yuge","year":"2011","journal-title":"Japanese J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2022.05.016_bib0037","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jsurg.2020.02.010","article-title":"The learning curve for transurethral resection of bladder tumour: how many is enough to be independent, safe and effective surgeon?","volume":"77","author":"Poletajew","year":"2020","journal-title":"J Surg Educ"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922001867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922001867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:24:35Z","timestamp":1761042275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922001867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1078143922001867"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.05.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}